title: [Clinical Efficacy of Decitabine Combined with Modified CAG Regimen for Relapse/Refractory Acute Myeloid Leukemia with AML1-ETO].
abstract: OBJECTIVE
  To investigate the clinical characteristics of patients with relapse-refractory acute myeloid leukemia(AML) with AML1-ETO+, and therapeutic effcacy and side effects of decitabine combined with modified CAG regimen.
  
  
  METHODS
  Clinical data of 8 cases of AML with AML1-ETO+from June 2015 to January 2016 were analyzed retrospectively, including age, sex, initial symptoms, peripheral blood and bone marrow characteristics and so on. at the same time, the therapeutic effcacy and side effects of decitabine combined with modified CAG regimen were evaluated. The 8 patient were with median age of 44.5(16-59) years.
  
  
  RESULTS
  Among these 8 patients, 1 patients were relapsed and other 7 patients were relapse/refractory patients, their median white blood cell count was 23.57(7.5-65.29)×109/L, median platelet count was 40(19-69)×109/L, median hemoglobin 1evel was 107(79-131) g/L, median lactate dehydrogenase level was 313.5(124.1-865.9) U/L at the initial diagnosis. The results showed that after treatment with decitabine combined with modified CAG, 7 patients achieved complete remission, 1 patient did not achieve remission, the overall remission rate was 87.5%(7/8). The main side effects of this regimen was myelosupp-ression, there were no new lung infection and other serious complications, 1 case without complete remission was treated with FLAG, and died of heart failure.
  
  
  CONCLUSIONS
  According to preliminary results of decitabine combined with modified CAG regimen for treatment of relapse/refractory AML patients with AMLl-ETO+displays higer remission rate and lower side effects.
authors: Jiangsu University, Zhenjiang 212013, Jiangsu Province, China; Department of Hematology, Changshu Municipal Second People's Hospital, Changshu 215500, Jiangsu Province, China.
authors: Qiang
authors: Q
authors: Liu
authors: Department of Hematology, The Affiliated Hospital of Jiangsu University (Zhenjiang Municipal Jiangbin Hospital), Zhenjiang 212008, Jiangsu Province, China. E-mail: feixiaomingujs@gmail.com.
authors: Xiao-Ming
authors: XM
authors: Fei
mesh_terms: D015250:Aclarubicin; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D001374:Azacitidine / Q000031:analogs & derivatives; D050676:Core Binding Factor Alpha 2 Subunit; D003561:Cytarabine; D000077209:Decitabine; D016179:Granulocyte Colony-Stimulating Factor; D006801:Humans; D015470:Leukemia, Myeloid, Acute; D007958:Leukocyte Count; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion; D000075142:RUNX1 Translocation Partner 1 Protein; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: C107844:AML1-ETO fusion protein, human; D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; D000075142:RUNX1 Translocation Partner 1 Protein; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D015250:Aclarubicin; D000077209:Decitabine; D001374:Azacitidine